Inmunómica traslacional en neoplasias hematológicas

Foto de Inmunómica traslacional en neoplasias hematológicas

Foto de Hospital General de Castellón

Hospital General de Castellón

Castelló de la Plana, España

Publicaciones en colaboración con investigadores/as de Hospital General de Castellón (5)

2021

A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia
Cancer, Vol. 127, Núm. 12, pp. 2003-2014
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia
Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

2009

The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients
Blood, Vol. 114, Núm. 20, pp. 4369-4372

2008

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Blood, Vol. 112, Núm. 10, pp. 4017-4023

2004

Incidence and characteristics of CD4+/HLA DRhi dendritic cell malignancies
Haematologica, Vol. 89, Núm. 1, pp. 58-69